Inhibrx Biosciences, Inc.

INBX

Held by 4 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

4 funds opened new positions. Next phase2 readout (INBRX-109): Sep 2025. Short interest: 29.2% of float.

Recent News & Research

bioRxiv

Multi-compartment immune and tumor cell reprogramming by IFNa2 overcomes colon cancer immunotherapy resistance

# Inhibrx Research Summary **Note:** I cannot access the specific content of this bioRxiv preprint, so I cannot provide an accurate analysis of its implications for INBX. To give you a meaningful investor summary, I would need either: (1) the full text or abstract, or (2) confirmation of INBX's involvement in this research. **What I can tell you:** If this research validates IFNα2 as overcoming colorectal cancer immunotherapy resistance, it could be clinically significant for checkpoint inhibitor-refractory patients—a substantial patient population. However, the commercial relevance to INBX specifically depends on whether they have IP, partnership, or development rights to this mechanism. **To provide proper analysis, please share:** - The abstract/key findings - Whether INBX is an author or has disclosed involvement - Current INBX pipeline status in onc

Jul 1, 2026

bioRxiv

Autoantibodies Drive Fc Gamma Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade

# Investment Summary: INBX Research Implications **Clinical Relevance:** This research elucidates a mechanistic pathway for immune checkpoint inhibitor (ICI)-induced colitis, a dose-limiting toxicity affecting patient tolerability and treatment duration. The study identifies autoantibody-driven, Fc gamma receptor-dependent inflammation as a key driver, potentially enabling targeted interventions to separate therapeutic from toxic effects of ICIs. **Commercial Implications for INBX:** If Inhibrx's pipeline includes Fc-modulating therapeutics or autoimmunity-focused assets, this mechanism could support clinical development strategies for ICI combination therapies or toxicity management. Understanding this pathway may also inform patient stratification or biomarker-driven approaches that could improve competitive positioning in the growing ICI space, though investors should verify direct pipeline relevance. **Key Consideration:** The preprint status (bioRxiv

Jun 7, 2026

Inhibrx Biosciences, Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research